IUI1:F:F-Intuitive Surgical Inc (EUR)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 397.3

Change

0.00 (0.00)%

Market Cap

USD 141.14B

Volume

35.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESL:F EssilorLuxottica Société ano..

N/A

USD 94.21B
ESLC:F ESSILORLUXOTTICA 1/2/O.N.

N/A

USD 93.89B
BOX:F Becton Dickinson and Company

N/A

USD 62.42B
HYB:F HOYA Corporation

N/A

USD 38.54B
HYB0:F HOYA CORP. ADR/ 1 O.N.

N/A

USD 38.45B
RMEA:F Resmed Inc DRC

N/A

USD 29.01B
RME:F ResMed Inc

N/A

USD 28.97B
CBHD:F Coloplast A/S

N/A

USD 25.77B
CBH:F COLOPLAST SP.ADR 1/10 DK1

N/A

USD 25.53B
TUO:F Terumo Corporation

N/A

USD 23.10B

ETFs Containing IUI1:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 29.43% 92% A 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.43% 84% B 80% B-
Trailing 12 Months  
Capital Gain 31.95% 93% A 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.95% 84% B 75% C
Trailing 5 Years  
Capital Gain -11.02% 39% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.02% 34% F 25% F
Average Annual (5 Year Horizon)  
Capital Gain 2.65% 60% D- 56% F
Dividend Return 2.65% 54% F 50% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.09% 20% F 22% F
Risk Adjusted Return 6.00% 54% F 45% F
Market Capitalization 141.14B 100% F 99% N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.